Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer
Gennigens, C.; Jerusalem, G.
Revue Medicale de Liege 66(7-8): 452-455
2011
ISSN/ISBN: 0370-629X PMID: 21942081 Document Number: 655678
Soft tissue sarcomas account for 1% of all malignant tumours. Until a few years ago, doxorubicine and ifosfamide were the only active chemotherapy drugs in the metastatic setting. Recently, a new drug has proven its efficacy after failure of standard treatments: the trabectedin; its activity is based on interference with ADN repair mechanisms. Trabectedin has just been also validated and reimbursed in patients with ovarian cancer, in partially sensitive recurrence. In this paper, we will review the mechanism of action and the clinical results of trabectedin.